BioCentury | May 29, 2020
Politics, Policy & Law

Proposed CMS rule for CAR Ts marks progress in reimbursing new technologies

It’s been four years since the first CAR T cell therapies were approved and inadequate reimbursement is still a barrier to access in the U.S. A new payment rule proposed by CMS aims to change...
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

A newly proposed payment model aims to increase reimbursement for cancer diagnostics by incentivizing companies to produce more clinical utility data. However, to drive widespread adoption, companies may also need to look to risk-sharing deals...
BC Extra | Nov 13, 2019
Politics & Policy

CMS, BIO spin Part B data in opposite directions

CMS and the biopharma industry are presenting conflicting explanations for a spike in Medicare Part B premiums and deductibles. CMS says the increases are “largely due to rising spending on physician-administered drugs” (see “Medicare Part...
BC Extra | Nov 11, 2019
Politics & Policy

Medicare Part B premium spike could create pressure for international reference pricing

The Trump administration Monday attributed a jump in Medicare Part B premiums and deductibles to increasing spending on physician-administered drugs. The administration is likely to use the increases to justify its proposal for an international...
BC Extra | Oct 31, 2019
Politics & Policy

CMS proposes coverage of next-generation sequencing for advanced cancer

CMS has proposed that next-generation sequencing should be covered for Medicare beneficiaries with advanced cancer. In a proposed decision memo , the agency said NGS as a diagnostic laboratory test when performed in a CLIA-certified laboratory...
BC Week In Review | Sep 20, 2019
Politics & Policy

HHS to review CMS approach to national security risks

HHS Acting Inspector General Joanne Chiedi wrote in a letter to Sens. Charles Grassley (R-Iowa) and Marco Rubio (R-Fla.) that the department will begin a review this fall to determine whether CMS has developed a...
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BC Innovations | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
BC Extra | Aug 7, 2019
Politics & Policy

CMS broadens coverage of CAR T therapies

After receiving 146 comments across two comment periods, CMS has opened up its coverage criteria for CAR Ts. In a final National Coverage Determination issued Wednesday, the Centers for Medicare & Medicaid Services said it...
BC Extra | Aug 6, 2019
Politics & Policy

How CMS plans to retool payments for antibiotics

CMS updated its payment system last week to make it easier for antibiotic companies to turn a profit, but the changes improve an already-established pathway rather than implementing an innovative subscription-based model as called for...
Items per page:
1 - 10 of 421
BioCentury | May 29, 2020
Politics, Policy & Law

Proposed CMS rule for CAR Ts marks progress in reimbursing new technologies

It’s been four years since the first CAR T cell therapies were approved and inadequate reimbursement is still a barrier to access in the U.S. A new payment rule proposed by CMS aims to change...
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

A newly proposed payment model aims to increase reimbursement for cancer diagnostics by incentivizing companies to produce more clinical utility data. However, to drive widespread adoption, companies may also need to look to risk-sharing deals...
BC Extra | Nov 13, 2019
Politics & Policy

CMS, BIO spin Part B data in opposite directions

CMS and the biopharma industry are presenting conflicting explanations for a spike in Medicare Part B premiums and deductibles. CMS says the increases are “largely due to rising spending on physician-administered drugs” (see “Medicare Part...
BC Extra | Nov 11, 2019
Politics & Policy

Medicare Part B premium spike could create pressure for international reference pricing

The Trump administration Monday attributed a jump in Medicare Part B premiums and deductibles to increasing spending on physician-administered drugs. The administration is likely to use the increases to justify its proposal for an international...
BC Extra | Oct 31, 2019
Politics & Policy

CMS proposes coverage of next-generation sequencing for advanced cancer

CMS has proposed that next-generation sequencing should be covered for Medicare beneficiaries with advanced cancer. In a proposed decision memo , the agency said NGS as a diagnostic laboratory test when performed in a CLIA-certified laboratory...
BC Week In Review | Sep 20, 2019
Politics & Policy

HHS to review CMS approach to national security risks

HHS Acting Inspector General Joanne Chiedi wrote in a letter to Sens. Charles Grassley (R-Iowa) and Marco Rubio (R-Fla.) that the department will begin a review this fall to determine whether CMS has developed a...
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BC Innovations | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
BC Extra | Aug 7, 2019
Politics & Policy

CMS broadens coverage of CAR T therapies

After receiving 146 comments across two comment periods, CMS has opened up its coverage criteria for CAR Ts. In a final National Coverage Determination issued Wednesday, the Centers for Medicare & Medicaid Services said it...
BC Extra | Aug 6, 2019
Politics & Policy

How CMS plans to retool payments for antibiotics

CMS updated its payment system last week to make it easier for antibiotic companies to turn a profit, but the changes improve an already-established pathway rather than implementing an innovative subscription-based model as called for...
Items per page:
1 - 10 of 421